Advertisement

Topics

Gemcabene for the Treatment of Pediatric NAFLD: A Phase 2a Study

2018-02-21 19:15:11 | BioPortfolio

Published on BioPortfolio: 2018-02-21T19:15:11-0500

Clinical Trials [1880 Associated Clinical Trials listed on BioPortfolio]

Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive...

The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease

The principal purpose of this study is to determine whether increased intakes of n-3 polyunsaturated (omega-3) fatty acids will reduce the amount of fat stored in the liver in patients wit...

Genetic Studies of Non-Alcoholic Fatty Liver Disease

Background: - Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions. Researchers want to study fatty liver disease b...

Study of Gemcabene in Adults With FPLD

The overall objective of this study is to assess the efficacy and safety of two dosing regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed by 600 mg...

Effect of Ginger Supplement on Non-alcoholic Fatty Liver

The hypothesis of this study was that ginger supplement consumption can be introduced as a new therapeutic strategy for non-alcoholic fatty liver disease through the improved body antioxid...

PubMed Articles [19538 Associated PubMed Articles listed on BioPortfolio]

Future therapy for non-alcoholic fatty liver disease.

Non-alcoholic fatty liver disease is a leading cause of chronic liver disease and can lead to cirrhosis, hepatocellular cancer and end stage liver disease. It is also associated with increased cardiov...

Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk.

With the advent and subsequent success of antiretroviral therapy, HIV infection has largely become a chronic condition and is increasingly seen alongside metabolic disorders such as dyslipidemia and i...

Serum magnesium concentration is independently associated with non-alcoholic fatty liver and non-alcoholic steatohepatitis.

The pathogenesis of non-alcoholic fatty liver disease (NAFLD) has not been well recognized yet.

Response to "Sleep habits and non-alcoholic fatty liver disease: risk assessment by adjusting confounders".

We thank Tomoyuki Kawada for the comments(1) in response to our recent article in Journal of Diabetes titled 'Short sleep duration and longer daytime napping are associated with non-alcoholic fatty li...

Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough.

Non-alcoholic fatty liver disease is a major cause of liver disease worldwide and the most common liver disorder in Western countries, affecting around 25% of the general population. Fibrosis is the m...

Medical and Biotech [MESH] Definitions

Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated.

Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.

Fatty liver finding without excessive ALCOHOL CONSUMPTION.

Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Cytoplasmic hyaline inclusions in HEPATOCYTES. They are associated with ALCOHOLIC STEATOHEPATITIS and non-alcoholic STEATOHEPATITIS, but are also present in benign and malignant hepatocellular neoplasms, and metabolic, toxic, and chronic cholestatic LIVER DISEASES.

More From BioPortfolio on "Gemcabene for the Treatment of Pediatric NAFLD: A Phase 2a Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial